tocilizumab for COVID-19: living meta-analysis of clinical studies

Study explorer (study characteristics and results) method abbreviations pdf xlsx

display ongoing studies
Study	Ref.	Design	studied treatment	control treatment	patients	study risk of bias	sample sizes	Results	deaths E	clinical improvement E	death or ventilation E
COVID-19 severe or critically meta-analysis
Rosas (REMDACTA) NCT04409262		RCT	tocilizumab	placebo	COVID-19 severe or critically	some concern	434/215	inconclusive
COVACTA (Rosas) NCT04320615		RCT	tocilizumab	placebo	COVID-19 severe or critically	some concern	301/151	suggested
1 study excluded by filtering options (1 RCT / 0 OBS)

PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).

Study explorer (study characteristics and results) method abbreviations pdf xlsx

COVID-19 severe or critically meta-analysis